AVEO Pharmaceuticals, Inc.
AVEO
AVEO was delisted on the 19th of January, 2023.
83 hedge funds and large institutions have $37.3M invested in AVEO Pharmaceuticals, Inc. in 2019 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 22 increasing their positions, 23 reducing their positions, and 25 closing their positions.
182% more call options, than puts
Call options by funds: $3.86M | Put options by funds: $1.37M
4% less repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 23
16% less funds holding
Funds holding: 99 → 83 (-16)
53% less capital invested
Capital invested by funds: $79.5M → $37.3M (-$42.1M)
60% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 25
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$847K |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$711K |
| 3 |
AIM
Assured Investment Management
New York
|
+$290K |
| 4 |
WA
WealthTrust Axiom
Wayne,
Pennsylvania
|
+$114K |
| 5 |
ARTA
A.R.T. Advisors
New York
|
+$107K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
-$4.01M |
| 2 |
6CM
683 Capital Management
New York
|
-$3M |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$554K |
| 4 |
FI
Fosun International
Hong Kong,
China
|
-$335K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$281K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
101
US Bancorp
Minneapolis,
Minnesota
| – | -$3K | -200 | Closed |
|
102
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$1.56K | -151 | Closed |
|
|
IA
103
IFP Advisors
Tampa,
Florida
| – | -$1K | -77 | Closed |
|
|
WEC
104
Winslow Evans & Crocker
Boston,
Massachusetts
| – | -$2K | -45 | Closed |
|
|
HR
105
Howe & Rusling
Rochester,
New York
| – | -$1K | -35 | Closed |
|
AVEO Hedge Fund Activity: Q1 2019 in Review
83 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in AVEO Pharmaceuticals, Inc. (AVEO) for Q1 2019, worth a combined $37.3M — down 53% from $79.5M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of AVEO and 10 opened new positions — a net loss of 15 holders — while 23 trimmed existing stakes and 22 added.
The largest buyer was Vanguard Group, adding an estimated $847K. The largest seller was Granahan Investment Management, exiting entirely with an estimated $4.01M sold.
- 83 institutional investors held AVEO Pharmaceuticals, Inc. (AVEO) as of Q1 2019, down from 99 in Q4 2018.
- Funds reported $37.3M of AVEO Pharmaceuticals, Inc. stock for Q1 2019, down 53% quarter-over-quarter.
- 10 funds opened new AVEO Pharmaceuticals, Inc. positions in Q1 2019 and 25 closed out, a net change of -15 holders.
- The largest AVEO Pharmaceuticals, Inc. buyer in Q1 2019 was Vanguard Group, an estimated $847K added.
- The largest AVEO Pharmaceuticals, Inc. seller in Q1 2019 was Granahan Investment Management, an estimated $4.01M sold.
Based on aggregated 13F filings for Q1 2019.